These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 33751403)

  • 1. Glycaemic Control with Insulin Glargine 300 U/mL in Individuals with Type 2 Diabetes and Chronic Kidney Disease: A REALI European Pooled Data Analysis.
    Mauricio D; Gourdy P; Bonadonna RC; Freemantle N; Bigot G; Mauquoi C; Ciocca A; Bonnemaire M; Müller-Wieland D
    Diabetes Ther; 2021 Apr; 12(4):1159-1174. PubMed ID: 33751403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Age on the Effectiveness and Safety of Insulin Glargine 300 U/mL: Results from the REALI European Pooled Data Analysis.
    Bonadonna RC; Mauricio D; Müller-Wieland D; Freemantle N; Bigot G; Mauquoi C; Ciocca A; Bonnemaire M; Gourdy P
    Diabetes Ther; 2021 Apr; 12(4):1073-1097. PubMed ID: 33650085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment.
    Javier Escalada F; Halimi S; Senior PA; Bonnemaire M; Cali AMG; Melas-Melt L; Karalliedde J; Ritzel RA
    Diabetes Obes Metab; 2018 Dec; 20(12):2860-2868. PubMed ID: 30003642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does Gender Influence the Effectiveness and Safety of Insulin Glargine 300 U/ml in Patients with Uncontrolled Type 2 Diabetes? Results from the REALI European Pooled Analysis.
    Gourdy P; Bonadonna RC; Freemantle N; Mauricio D; Müller-Wieland D; Bigot G; Mauquoi C; Ciocca A; Bonnemaire M
    Diabetes Ther; 2022 Jan; 13(1):57-73. PubMed ID: 34784005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database.
    Müller-Wieland D; Freemantle N; Bonadonna RC; Mauquoi C; Bigot G; Bonnemaire M; Gourdy P; Mauricio D
    Diabetes Ther; 2023 Feb; 14(2):401-413. PubMed ID: 36596946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis.
    Haluzík M; Seufert J; Guja C; Bonnemaire M; Bigot G; Tournay M; Kis JT; Freemantle N
    Diabetes Ther; 2023 Apr; 14(4):639-652. PubMed ID: 36787044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12-month comparison by concomitant sulphonylurea and/or glinide use.
    Terauchi Y; Riddle MC; Hirose T; Koyama M; Cheng X; Takahashi Y; Bolli GB
    Diabetes Obes Metab; 2018 Nov; 20(11):2541-2550. PubMed ID: 29888454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
    Owens DR; Bolli GB; Charbonnel B; Haak T; Landgraf W; Porcellati F; Traylor L; Kautzky-Willer A
    Diabetes Obes Metab; 2017 Nov; 19(11):1546-1554. PubMed ID: 28449412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension).
    Terauchi Y; Koyama M; Cheng X; Sumi M; Riddle MC; Bolli GB; Hirose T;
    Diabetes Metab; 2017 Oct; 43(5):446-452. PubMed ID: 28433560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin Glargine Combined with Oral Antidiabetic Drugs for Asians with Type 2 Diabetes Mellitus: A Pooled Analysis to Identify Predictors of Dose and Treatment Response.
    Gu T; Hong T; Zhang P; Tang S; Bi Y; Lu H; Men L; Ma D; Zhu D
    Diabetes Ther; 2018 Apr; 9(2):771-787. PubMed ID: 29524190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes.
    Suzuki K; Mitsuma Y; Sato T; Anraku T; Hatta M
    J Clin Med Res; 2016 Nov; 8(11):805-814. PubMed ID: 27738482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
    Xie L; Wei W; Pan C; Baser O
    J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness of insulin glargine 300 U/mL among type 2 diabetes patients: Analysis of a real-world data in Israel.
    Melzer Cohen C; Banon T; Shalev V; Chodick G
    Endocrinol Diabetes Metab; 2020 Jul; 3(3):e00124. PubMed ID: 32704550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes.
    Kovatchev B; Meng Z; Cali AMG; Perfetti R; Breton MD
    Diabetes Ther; 2020 Jun; 11(6):1293-1302. PubMed ID: 32304086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
    Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
    Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naive individuals with type 2 diabetes mellitus.
    Frier BM; Landgraf W; Zhang M; Bolli GB; Owens DR
    Diabetes Obes Metab; 2018 Dec; 20(12):2894-2898. PubMed ID: 29943493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen.
    Bolli GB; Wysham C; Fisher M; Chevalier S; Cali AMG; Leroy B; Riddle MC
    Diabetes Obes Metab; 2019 Feb; 21(2):402-407. PubMed ID: 30160030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo
    Wiesli P; Schories M
    Diabetes Ther; 2018 Dec; 9(6):2325-2334. PubMed ID: 30302721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.
    Davies M; Evans R; Storms F; Gomis R; Khunti K
    Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.